Latest Conference Coverage

Building Community and Education Through the AMDAPP CME Conference: Kinsey McCartney, PA-C

The physician assistant at UCSF Movement Disorder and Neuromodulation Center reflected on the value of AMDAPP in fostering professional connection, education, and patient-centered care among movement disorder APPs. [WATCH TIME: 3 minutes]

Phase 1 Study Supports Further Development of LRRK2 Inhibitor ARV-102

Challenges in Treating Genetically Predisposed Alzheimer Disease: Insights from APOLLOE4

Emer MacSweeney, MD, a consultant neuroradiologist and trial investigator of the phase 3 APOLLOE4 study, provided a clinical view of the latest study findings, and the difficulties with finding treatments for APOEε4/4 carriers of Alzheimer disease.

Exploring Noninvasive Brain Stimulation for Neurorehabilitation: Roy H. Hamilton, MD, MS, FAAN

The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed the current research landscape, clinical challenges, and future directions for noninvasive neuromodulation techniques in neurorehabilitation. [WATCH TIME: 4 minutes]

Educating the Clinical Community on Differences in Alzheimer Diagnostic Criteria: Clifford Jack, MD

The neuroradiologist at Mayo Clinic provided clinical insights on the controversy with two recently published Alzheimer criteria, with one diagnosing the disease based on biomarkers alone vs clinical symptoms. [WATCH TIME: 4 minutes]

Next-Gen Gene Editing for Muscular Dystrophy: Exploring the ARCUS Approach

Cassandra Gorsuch, PhD, chief scientific officer at Precision Biosciences, discussed the company’s ARCUS gene editing platform, its innovative approach to treating Duchenne muscular dystrophy, and promising preclinical data presented at MDA 2025.

Translating Oculopharyngeal Muscular Dystrophy Research Into Clinical Application: Matthew Wicklund, MD

The professor of neurology at the University of Texas Health Science Center San Antonio discussed some of the challenges with therapeutic development for OPMD, as well as advances and barriers to gene therapy approaches. [WATCH TIME: 4 minutes]

The Key Role of Early and Balanced Blood Pressure Control in ICH Management: Kara R. Melmed, MD

The clinical associate professor of neurology and neurosurgery at NYU Langone Health emphasized the importance of rapid, targeted blood pressure reduction and bundled care to improve outcomes in patients with intracerebral hemorrhage. [WATCH TIME: 4 minutes]

AXS-07 Outperforms Other CGRP-Targeting Gepants in Meta-Analysis

Relative to previously approved therapies like rimegepant, ubrogepant, and zavegepant, AXS-07 resulted in better 2-hour pain relief, sustained pain relief, and reduced use of rescue medications.

Understanding the Cellular Drivers of MS Progression and Treatment Response: Amit Bar-Or, MD, FRCPC, FAAN, FANA

The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania discussed evolving insights into the cellular immunology of multiple sclerosis. [WATCH TIME: 4 minutes]

Phase 3 Study to Test 1st Generation Antihistamine EPX-100 in Lennox-Gastaut Syndrome

Harmony Biosciences’ phase 3 study will assess EPX-100, a repurposed antihistamine, as a potential treatment for Lennox-Gastaut syndrome, targeting seizure reduction and improved outcomes.

NeuroVoices: Chitra Venkatasubramanian, MBBS, MD, MSc, FNCS, on Debating Optimal Blood Pressure Targets After Intracerebral Hemorrhage

The clinical professor of stroke neurology at Stanford University discussed the clinical rationale and evidence supporting early, intensive blood pressure lowering in patients with intracerebral hemorrhage.

Overviewing Valiltramiprosate’s Therapeutic Impact on Volumetric Imaging MRI, Diffusion Tensor Imaging in Alzheimer Disease

Murali Doraiswamy, MD, MBBS, a professor of psychiatry and geriatrics at Duke University School of Medicine, gave clinical follow-up on a pivotal analysis of the phase 3 APOLLOE4 study testing a novel therapeutic for Alzheimer disease.

ZYN002 Gel Shows Long-Term Safety and Behavioral Improvements in Fragile X Syndrome

Newly presented open-label extension results at AAN 2025 suggest that investigational ZYN002, a cannabidiol gel, may help improve irritability in children and adolescents living with Fragile X syndrome.

Advancing Preclinical Alzheimer Research Through AI and Behavioral Analysis: Stephanie R. Miller, PhD

The staff scientist at Gladstone Institutes talked about leveraging AI-driven behavioral analysis to better model and assess Alzheimer disease progression in preclinical studies. [WATCH TIME: 2 minutes]

IPX203 Boosts “Good ON” Time in Parkinson Disease, Especially in Patients on Lower Dopamine Agonist Doses

Findings from a phase 3 study revealed that patients with Parkinson disease switching to IPX203 had greater benefits in good ON time when also taking lower doses of dopamine agonists.

GLP-1 Analogs Showing Broad Neuroprotective Potential Across Neurological Disorders: Paul Edison, MBBS, PhD, FRCPI

The professor of neuroscience at the Imperial College London discussed the emerging role of GLP-1 analogs as neuroprotective agents with potential benefits in neurodegenerative conditions. [WATCH TIME: 4 minutes]

CGRP Therapies as Potential First-Line Migraine Preventive Treatment: Andrew Charles, MD

The director of the UCLA Goldberg Migraine Program discussed the advantages, evidence base, and evolving payor support for CGRP-targeting therapies as potentially a first-line option in migraine prevention. [WATCH TIME: 5 minutes]

Aggressive Blood Pressure Lowering for Intracerebral Hemorrhage Management: Chitra Venkatasubramanian, MBBS, MD, MSc, FNCS

The clinical professor of stroke neurology and neurocritical care at Stanford University advocated for early and intensive blood pressure reduction in patients with intracerebral hemorrhage to limit hematoma expansion and improve outcomes. [WATCH TIME: 5 minutes]

Newly Launched Phase 4 ENABLE Trial to Test Real-World Efficacy of Ublituximab in Relapsing Multiple Sclerosis

The ENABLE phase 4 study will evaluate the real-world safety, efficacy, and patient experience of ublituximab in relapsing multiple sclerosis over a 96-week period.

Complement-Targeting Agent ANX005 Demonstrates Therapeutic Efficacy in Phase 3 Study of Guillain-Barré Syndrome

Presented at the 2025 AAN Annual Meeting, findings from a phase 3 study showed that a single 30 mg/kg dose of ANX005 significantly improved health outcomes in Guillain-Barré syndrome, with benefits seen as early as week 1 and sustained over 6 months.

Post Hoc Analysis of ADVANCE Trial Reveals Atogepant Improves Functional Outcomes in Migraine

Findings showed that atogepant 60 mg once daily demonstrated significant improvements in functional outcomes for patients with episodic migraine, compared with placebo, over 12 weeks.

Two-Year Open-Label Data Highlight Frexalimab’s Impact on Disease Activity in Relapsing Multiple Sclerosis

Long-term data from a phase 2 study extension suggest that frexalimab, a CD40L inhibitor, maintains disease control and is well-tolerated in relapsing multiple sclerosis, reinforcing its potential as a next-generation treatment.

The Evolving and Emerging Role of Plasma Biomarkers in Diagnosing and Monitoring Alzheimer Disease

Inge Verberk, PhD, a research associate at the Amsterdam University Medical Center, sat down at AD/PD 2025 to discuss changes in Alzheimer trials, the emergence of plasma biomarkers, and deciphering which biomarkers are of utmost importance.

Study Reveals Impact of Early Adversity on Coping, Mental Health, and Cognition

A recent large-scale analysis presented at the 2025 AD/PD Conference highlighted the role of coping strategies in mitigating negative outcomes.

Baseline Analysis of MINDFuL Trial Highlights Screening Success of Enrolling Patients With Immune Dysfunction

Data suggests that immune dysfunction biomarkers do not pose a major barrier to patient enrollment in Alzheimer’s research, as most patients meeting general AD criteria also qualified under immune dysfunction criteria.

Novel IVD Tool for Rapid APOE Genotyping May Aid in Alzheimer Disease Risk Stratification

A recent poster presentation at the 2025 AD/PD conference revealed that a novel assay could provide absolute allelic discrimination for APOE genotyping, supporting precision medicine in AD treatment.

Sweden Analysis Reveals Key Lifestyle and Socioeconomic Factors Driving Cognitive Decline

An analysis of the Gothenburg Mild Cognitive Impairment Study presented at the 2025 AD/PD Conference reported that lifestyle and socioeconomic factors could significantly influence the risk of developing cognitive diseases.

Survey Study Aims to Assess Germany’s Readiness for Early Alzheimer Diagnosis Using Biomarkers

A new survey study will assess how well German memory clinics and specialists are equipped to provide early and accurate Alzheimer diagnoses using biomarker-based methods.

Cognito’s Gamma Sensory Stimulation Leads to Preserved Corpus Callosum Structure in Alzheimer Disease

The Spectris device demonstrated preserved corpus callosum structure and correlated sensory-evoked gamma oscillations in patients with Alzheimer disease, highlighting its potential neuroprotective effects.